

Provider Perspective on the Use of Topical Pain Products

***Committee to Assess the Available Scientific Data
Regarding the Safety and Effectiveness of Ingredients
used in Compounded Topical Pain Creams***

Washington, DC


May 20, 2019; 3:10-3:00pm

Robert J. Dimeff, MD
Texas Orthopaedic Associates
Team Physician Dallas Stars
Past President AMSSM



Introduction

- Traumatic injuries
 - ◆ Violent
 - ◆ Collision vs Noncollision
 - ◆ Fractures, Sprains, Strains



trau
Cho
end


Introduction

Evidence Based Medicine

- Stresses the importance of evidence derived from high quality clinical research rather than expert opinion and nonsystematic clinical observations *Gordon Guyatt 1990*
- The conscientious, explicit and judicious use of the “current best evidence” in making the best decision about the care of the individual patient *DL Sackett 1997*

Introduction

Evidence Based Medicine



Treatment Strategy

- Consider the differential diagnosis
- Myofascial pain and dysfunction of muscle
- Intra articular disorders
- Compensatory nerve entrapment not uncommon
- Paradigm shift: change tissue back to normal
- Maximize nonoperative, noninvasive, least expensive, least risk treatment; except for pros
- Painful, invasive, expensive treatments have a bigger placebo effect

Treatment Options

- Rehab exercises
- Fix underlying cause
- Behavioral modification
- Biomechanics & braces
- Moist heat
- Cryotherapy
- Electrical/Galvanic stim
- Ultrasound
- Laser
- RF ablation
- Dry needle/TPI
- Magnets
- Chiropractic
- ART/MAT
- Massotherapy
- Acupuncture

Treatment Options

- Diet & supplements
- Medications
- NTG patches
- Steroid injections
- Hyaluronic acid
- Shockwave therapy
- Prolotherapy
- Autologous blood
- Platelet rich plasma
- Amniotic tissue
- BMAC
- Fat derived “stem” cell
- Umbilical cord products
- Exosomes
- CBT/psych
- Prayer

Treatment Options

- Diet & supplements
- **Medications**
- NTG patches
- Steroid injections
- Hyaluronic acid
- Shockwave therapy
- Prolotherapy
- Autologous blood
- Platelet rich plasma
- Amniotic tissue
- BMAC
- Fat derived “stem” cell
- Umbilical cord products
- Exosomes
- CBT/psych
- Prayer

Pain Medication in Orthopedics

Administration

- Intravenous
- Inhalation
- Intramuscular
- Oral
- Rectal
- Transdermal
- Topical

Classes

- Narcotics
- Anesthetics/caines
- NSAIDS
- TCA
- SSRI/SNRI
- Neuroleptics
- Miscellaneous

Pain Medication in Orthopedics

Administration

- Intravenous
- Inhalation
- Intramuscular
- Oral
- Rectal
- Transdermal
- **Topical**

Classes

- Narcotics
- Anesthetics/caines
- NSAIDS
- TCA
- SSRI/SNRI
- Neuroleptics
- Miscellaneous

Topical


- OTC
- NSAIDS
- Rx
- Compounded



Composition (100 g Ointment contain)	Ø	
Arnica Montana	D2	1,5 g
Calendula officinalis	Ø	0,45 g
Hamamelis virginiana	Ø	0,45 g
Echinacea angustifolia	Ø	0,15 g
Echinacea purpurea	Ø	0,15 g
Chamomilla recutita	Ø	0,15 g
Symphytum officinale	D4	0,1 g
Bellis perennis	Ø	0,1 g
Hypericum perforatum	D6	0,09 g
Achillea millefolium	Ø	0,09 g
Aconitum napellus	D1	0,05 g
Atropa belladonna	D1	0,05 g
Mercurius solubilis Hahnemanni	D6	0,04 g
Hepar sulfuris	D6	0,025 g

Topical

- OTC
- NSAIDS
- Rx
- Compounded



Composition (100 g Ointment contain)	Ø	
Arnica Montana	D2	1,5 g
Calendula officinalis	Ø	0,45 g
Hamamelis virginiana	Ø	0,45 g
Echinacea angustifolia	Ø	0,15 g
Echinacea purpurea	Ø	0,15 g
Chamomilla recutita	Ø	0,15 g
Symphytum officinale	D4	0,1 g
Bellis perennis	Ø	0,1 g
Hypericum perforatum	D6	0,09 g
Achillea millefolium	Ø	0,09 g
Aconitum napellus	D1	0,05 g
Atropa belladonna	D1	0,05 g
Mercurius solubilis Hahnemanni	D6	0,04 g
Hepar sulfuris	D6	0,025 g

Compounded Topicals

Global Market Insights
Insights to innovation.

COMPOUNDING PHARMACIES MARKET

COMPOUNDING PHARMACIES INDUSTRY TO SURPASS **\$12.5 BN** BY 2024

INDUSTRY SIZE (2017)



>\$8.5 BN



**CAGR
(2018-24)**

Compounding pharmacies market share
from geriatric applications



6.7% CAGR (2018-24)

U.S. led NA landscape
generating a revenue
of \$4,781.2 MN in 2017



Compounded Topicals

Ingredients

- NSAIDS - keto, ibupr, piroxicam, diclofenac
- Relaxants - cyclobenz, baclofen, guaifenasin
- Vasodilate - nifedipine, verapamil
- Pain blockers - ketamine, opiates, caines
- Neuro - amitriptyline, gabapentin
- Misc - capsaicin, menthol, clonidine, filler
- Carrier - lipoderm gel, PLO cream

Compounded Topicals

Personal Use in Sports Medicine

- Have recommended for chronic MSK disorders
- Most
 - ◆ Re
- Do t
than



ibe
dence
etter

Compounded Topicals

Efficacy

- N=133 Neuro, Nociceptive, Mixed Lido+
 - ◆ N=ketamine, gabapentin, clonidine
 - ◆ No=ketoprofen, baclofen, cyclobenzaprine
 - ◆ M=keta, gaba, diclofenac, bac, cyclob
- 36% vs 28% decrease in pain (≥ 2) at 30 days

Compound pain creams are not better than placebo cream, and their higher costs compared to approved compounds should curtail routine use



Compounded Topicals

Personal Use in Sports Medicine

- Have recommended for chronic MSK disorders
- Most physicians don't know how to prescribe
 - ◆ Rely on industry to recommend with little evidence
- Do they work? Efficacy less than, equal, better than other delivery systems?
 - ◆ Application method is therapeutic

Compounded Topicals

Personal Use in Sports Medicine

- Safer than other deliver systems?
 - ◆ Source, purity, contaminants, production, control, dermatologic issues, dose and frequency concerns
- Less expensive?
 - ◆ \$100s to \$1000s per tube charged to insurance
- Not better results than other topical agents

As a result, namely efficacy and expense, I have curtailed my use of compounded topicals

Thank You

